Epidemiology of myeloproliferative neoplasms in the United States

Leukemia and Lymphoma

Volumn 55, Issue 3, 2014, Pages 595-600

  Mehta, Jyotsna ^a   Wang, Hongwei ^a   Iqbal, Sheikh Usman ^a   Mesa, Ruben ^b  

^a Sanofi   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Epidemiology; Essential thrombocythemia; Myelofibrosis; Polycythemia; Vera

Indexed keywords

ADULT; AGED; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYELOPROLIFERATIVE DISORDERS; PREVALENCE; UNITED STATES;

EID: 84894415792     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.813500     Document Type: Article

References (21)

1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-1097
2. Mesa RA, Verstovsek S, Cervantes F, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007;31:737-740
3. Vener C, Fracchiolla NS, Gianelli U, et al. Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis. Blood 2008;111:1862-1865
4. Mesa RA, Li CY, Ketterling RP et al. Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases. Blood 2005 ; 105 : 973-977
5. Mesa RA, Schwager S, Radia D, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009;33:1199-1203
6. Scherber R, Dueck AC, Johansson P et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. Blood 2011 ; 118 : 401-408
7. Passamonti F, Rumi E, Pungolino E, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004 ; 117 : 755-761
8. Breslow NE, Day NE. Indirect standardization and multiplicative models for rates, with reference to the age adjustment of cancer incidence and relative frequency data. J Chron Dis 1975;28: 289-303
9. Johansson P, Kutti J, Andreasson B, et al. Trends in the incidence of chronic Philadelphia chromosome negative (Ph-) myeloproliferative disorders in the city of Goteborg, Sweden, during 1983-99. J Intern Med 2004;256:161-165
10. Mesa RA, Silverstein MN, Jacobsen SJ, et al. Population-based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: an Olmsted county study, 1976-1995. Am J Hematol 1999 ; 61 : 10-15
11. Girodon F, Bonicelli G, Schaeffer C, et al. Significant increase in the apparent incidence of essential thrombocythemia related to new WHO diagnostic criteria: a population-based study Haematologica, 2009, 94, 865-869
12. Phekoo KJ, Richards MA, Moller H, et al. The incidence and outcome of myeloid malignancies in 2,112 adult patients in southeast England . Haematologica 2006 ; 91 : 1400-1404
13. Rollison DE , Howlader N, Smith MT, et al . Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008 ; 112 : 45-52
14. Policitemia GIS. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-664
15. Passamonti F, Rumi E, Arcaini L, et al. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645-1651
16. Cervantes F, Passamonti F, Barosi G. Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. Leukemia 2008 ; 22 : 905-914
17. Berglund S, Zettervall O. Incidence of polycythemia vera in a defined population. Eur J Haematol 1992;48:20-26
18. Bender GP, Young D, Balcerzak SP. Polycythemia vera in a small Ohio town. Ohio State Med J 1986 ;82 : 631, 633-635
19. Ma X, Vanasse G, Cartmel B, et al. Prevalence of polycythemia vera and essential thrombocythemia. Am J Hematol 2008 ; 83 : 359-362
20. Jensen MK, de Nully Brown P, Nielsen OJ, et al. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2002 ; 65 : 132-139
21. Abdel-Wahab OI, Levine RL. Primary myelofibrosis: update on definition, pathogenesis, and treatment . Annu Rev Med 2009; 60 : 233-245 .